Next Century Growth Investors LLC Has $8.07 Million Stock Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Next Century Growth Investors LLC lifted its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 66.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 310,658 shares of the medical equipment provider's stock after acquiring an additional 124,267 shares during the quarter. Next Century Growth Investors LLC owned about 0.67% of BioLife Solutions worth $8,065,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in BLFS. Raymond James Financial Inc. bought a new stake in shares of BioLife Solutions in the 4th quarter worth about $20,664,000. Massachusetts Financial Services Co. MA acquired a new stake in BioLife Solutions during the fourth quarter valued at approximately $19,805,000. Rockefeller Capital Management L.P. lifted its holdings in BioLife Solutions by 40.4% during the 4th quarter. Rockefeller Capital Management L.P. now owns 821,764 shares of the medical equipment provider's stock worth $21,333,000 after buying an additional 236,267 shares during the last quarter. Victory Capital Management Inc. raised its stake in BioLife Solutions by 422.2% during the fourth quarter. Victory Capital Management Inc. now owns 218,962 shares of the medical equipment provider's stock worth $5,684,000 after acquiring an additional 177,028 shares during the period. Finally, Mutual of America Capital Management LLC lifted its stake in BioLife Solutions by 31.2% in the fourth quarter. Mutual of America Capital Management LLC now owns 521,937 shares of the medical equipment provider's stock valued at $13,549,000 after buying an additional 124,165 shares during the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. HC Wainwright increased their price objective on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Northland Securities raised their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a research note on Wednesday, January 8th. StockNews.com upgraded BioLife Solutions from a "sell" rating to a "hold" rating in a research report on Tuesday, April 8th. Finally, Benchmark restated a "buy" rating and issued a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $31.17.

BioLife Solutions Price Performance

Shares of BLFS traded up $0.35 during midday trading on Tuesday, reaching $22.43. The stock had a trading volume of 438,383 shares, compared to its average volume of 375,368. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The company has a market capitalization of $1.05 billion, a P/E ratio of -21.16 and a beta of 1.93. The firm's 50 day moving average price is $24.87 and its 200-day moving average price is $25.31. BioLife Solutions, Inc. has a 52 week low of $14.84 and a 52 week high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.32. The firm had revenue of $22.71 million for the quarter, compared to analysts' expectations of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same period in the previous year, the business earned ($0.21) earnings per share. On average, analysts forecast that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Insider Buying and Selling at BioLife Solutions

In other news, insider Sarah Aebersold sold 2,695 shares of BioLife Solutions stock in a transaction on Monday, March 17th. The stock was sold at an average price of $25.44, for a total transaction of $68,560.80. Following the transaction, the insider now owns 43,165 shares in the company, valued at approximately $1,098,117.60. The trade was a 5.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Troy Wichterman sold 25,687 shares of the stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total value of $582,067.42. Following the completion of the sale, the chief financial officer now directly owns 189,242 shares of the company's stock, valued at approximately $4,288,223.72. This represents a 11.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 72,127 shares of company stock valued at $1,676,533. 2.20% of the stock is currently owned by corporate insiders.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.